disease interaction(s) of obesity with HFpEF
Jump to navigation
Jump to search
Introduction
Interactions:
- chronic hypertension & HFpEF are more common in obese patients
Management
- BMI should not be a factor in selecting antihypertensive therapy[1]
- tirzepatide decreases risk of worsening heart failure or cardiovascular death in obese with HFpEF[2]
More general terms
References
- ↑ 1.0 1.1 Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials. Lancet 2014 Nov 4; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25468168 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961171-5/fulltext
Franklin SS and Weber MA. Optimum antihypertensive therapy: Does adiposity matter? Lancet 2014 Nov 4; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25468165 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961336-2/fulltext - ↑ 2.0 2.1 Packer M, Zile MR, Kramer CM et l Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2024 Nov 16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39555826 https://www.nejm.org/doi/10.1056/NEJMoa2410027